董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Hui Liu | 男 | Director | 53 | 5.47万美元 | 2.10 | 2026-06-30 |
| Helen M. Boudreau | 女 | Director | 60 | 6.22万美元 | 1.39 | 2026-06-30 |
| Lucian Iancovici | 男 | Director | 43 | 未披露 | 未持股 | 2026-06-30 |
| Stephen Uden | 男 | Chief Executive Officer and Director and President | 68 | 115.70万美元 | 18.25 | 2026-06-30 |
| Wendy K. Chung | 女 | Director | 57 | 5.12万美元 | 未持股 | 2026-06-30 |
| Martin W. Mackay | 男 | Chairman of the Board and Director | 69 | 29.72万美元 | 18.49 | 2026-06-30 |
| Robert Hopfner | 男 | Director | 53 | 5.87万美元 | 32.15 | 2026-06-30 |
| Christine A. Nash | 女 | Director | 53 | 5.98万美元 | 1.12 | 2026-06-30 |
| Ronald Hunt | 男 | Director | 61 | 5.87万美元 | 44.64 | 2026-06-30 |
| Paula Soteropoulos | 女 | Director | 58 | 8.27万美元 | 1.46 | 2026-06-30 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Stephen Uden | 男 | Chief Executive Officer and Director and President | 68 | 115.70万美元 | 18.25 | 2026-06-30 |
| Jonathan I. Lieber | 男 | Chief Financial Officer and Treasurer | 56 | 86.88万美元 | 4.88 | 2026-06-30 |
董事简历
中英对照 | 中文 | 英文- Hui Liu
-
Hui Liu自2015年12月起担任我们的首席商务官，自2018年10月起担任Merus U.S.的负责人。刘博士的职责包括业务发展的各个方面，包括内部和外部许可、收购和联盟管理，以及Merus在美国的扩张，在加入Merus之前，刘博士曾担任制药公司Novartis AG的Vice President和肿瘤学业务开发与许可全球主管，2013年至2015年，2009年至2012年，担任疫苗和诊断业务开发和许可Vice President兼全球主管。任职Novartis公司之前，Liu博士曾担任Pfizer公司（制药公司）的多种管理职务（从2004年到2009年），以及Pfizer公司及其前身公司Warner-Lambert公司（从1997年到2001年）。从2001年到2004年，刘博士是高盛集团（Goldman Sachs）和花旗集团（Citigroup）的投资银行家。Liu博士拥有密歇根大学（University of Michigan）分子生物学博士学位和金融学工商管理硕士学位以及北京大学（Peking University）生物学学士学位。
Hui Liu as served as a member of Rallybio's Board since April 2022. Dr Liu has been the Chief Executive Officer and board member of Olethros B.V. since August 2025. Dr. Liu has also been Chief Operating and Business Officer of Gyes B.V. since August 2025. Until July 2024, Dr. Liu was Chief Business Officer since December 2015 and Head of Merus U.S. since October 2018 of Merus N.V., a clinical stage oncology company. From 2013 to 2015, Dr. Liu served as Vice President and Global Head, Business Development & Licensing, Oncology, and from 2009 to 2012 as Vice President and Global Head, Business Development & Licensing, Vaccines & Diagnostics, at Novartis AG. Prior to Novartis, Dr. Liu held positions of increasing responsibility in business development at Pfizer from 2004 to 2009 and in the R&D organization at Pfizer and its predecessor company Warner Lambert from 1997 to 2001. From 2001 to 2004, Dr. Liu was an investment banker at Goldman Sachs and Citigroup. Dr. Liu received a Ph.D. in molecular biology and an M.B.A. in finance from the University of Michigan and a B.S. in biology from Peking University. - Hui Liu自2015年12月起担任我们的首席商务官，自2018年10月起担任Merus U.S.的负责人。刘博士的职责包括业务发展的各个方面，包括内部和外部许可、收购和联盟管理，以及Merus在美国的扩张，在加入Merus之前，刘博士曾担任制药公司Novartis AG的Vice President和肿瘤学业务开发与许可全球主管，2013年至2015年，2009年至2012年，担任疫苗和诊断业务开发和许可Vice President兼全球主管。任职Novartis公司之前，Liu博士曾担任Pfizer公司（制药公司）的多种管理职务（从2004年到2009年），以及Pfizer公司及其前身公司Warner-Lambert公司（从1997年到2001年）。从2001年到2004年，刘博士是高盛集团（Goldman Sachs）和花旗集团（Citigroup）的投资银行家。Liu博士拥有密歇根大学（University of Michigan）分子生物学博士学位和金融学工商管理硕士学位以及北京大学（Peking University）生物学学士学位。
- Hui Liu as served as a member of Rallybio's Board since April 2022. Dr Liu has been the Chief Executive Officer and board member of Olethros B.V. since August 2025. Dr. Liu has also been Chief Operating and Business Officer of Gyes B.V. since August 2025. Until July 2024, Dr. Liu was Chief Business Officer since December 2015 and Head of Merus U.S. since October 2018 of Merus N.V., a clinical stage oncology company. From 2013 to 2015, Dr. Liu served as Vice President and Global Head, Business Development & Licensing, Oncology, and from 2009 to 2012 as Vice President and Global Head, Business Development & Licensing, Vaccines & Diagnostics, at Novartis AG. Prior to Novartis, Dr. Liu held positions of increasing responsibility in business development at Pfizer from 2004 to 2009 and in the R&D organization at Pfizer and its predecessor company Warner Lambert from 1997 to 2001. From 2001 to 2004, Dr. Liu was an investment banker at Goldman Sachs and Citigroup. Dr. Liu received a Ph.D. in molecular biology and an M.B.A. in finance from the University of Michigan and a B.S. in biology from Peking University.
- Helen M. Boudreau
-
Helen M.Boudreau于2020年6月加入我们。Boudreau女士在生物技术、制药、咨询和银行业拥有30年的经验。最近，从2018年6月至2019年6月，她担任非营利生物技术比尔及梅林达·盖茨医学研究所的首席运营官。此前，她曾于2017年7月至2018年6月担任首席财务官，并于2016年2月至2017年7月担任ProteostasisTherapeutics，Inc.董事兼审计委员会主席2014年10月至2017年6月，她担任Forma Therapeutics，Inc.的首席财务官。2008年9月至2014年9月，Boudreau女士在Novartis担任高级财务职位，包括首席财务官Novartis Corporation US和首席财务官Global Oncology。从1999年4月到2008年9月，Boudreau女士在辉瑞公司（Pfizer）担任越来越多的战略与财务方面的职务和责任，包括Vice President金融客户业务部和商业运营部以及辉瑞全球研究与开发Vice President金融公司。Boudreau女士在百事可乐/百胜餐饮集团（PepsiCo/Yum！Brands，麦肯锡公司和美国银行。自2020年6月以来，她一直担任梦百合改进公司Premier，Inc.的董事会成员。她也任职Shattuck Labs公司、Field Trip Health公司、Rallybio公司的董事会。Boudreau女士在马里兰大学（University of Maryland）以优异成绩毕业并获得经济学学士学位，在弗吉尼亚大学（University of Virginia）达顿商学院（Darden Graduate School of Business）获得工商管理硕士学位。
Helen M. Boudreau has served as a member of Rallybio's Board since September 2020. Since 2020, she has been Managing Director of Estuary Ventures LLC, providing board and advisory services. Previously, she served as Chief Financial Officer from July 2017 to June 2018 and as a board member from February 2016 to July 2017 of Proteostasis Therapeutics, Inc. From October 2014 to June 2017, Ms. Boudreau served as Chief Financial Officer of FORMA Therapeutics, Inc., and from September 2008 to September 2014, Ms. Boudreau served in senior finance roles at Novartis AG, including Chief Financial Officer Novartis Corporation US and Chief Financial Officer Global Oncology. Prior to Novartis, Ms. Boudreau served in roles of increasing responsibility in strategy and finance at Pfizer from April 1999 to September 2008, including Vice President Finance Customer Business Unit and Commercial Operations and Vice President Finance, Pfizer Global Research and Development. Earlier in her career, Ms. Boudreau worked at PepsiCo Inc. and YUM! Brands, Inc., McKinsey & Company and Bank of America Corporation. Ms. Boudreau currently serves as a board member of Shattuck Labs Inc. Ms. Boudreau previously served on the board of directors of Premier, Inc., Cara Therapeutics, Inc., Evaxion Biotech A/S, Proteostasis Therapeutics, Inc. and Reunion Neuroscience Inc. Ms. Boudreau earned a B.A. in Economics from the University of Maryland, where she graduated summa cum laude, and an M.B.A. from the Darden Graduate School of Business at the University of Virginia. Ms. Boudreau is Directorship Certified by the National Association of Corporate directors ("NACD") and earned the CERT Certificate in Cybersecurity Oversight from Carnegie Mellon University Software Engineering Institute and NACD. - Helen M.Boudreau于2020年6月加入我们。Boudreau女士在生物技术、制药、咨询和银行业拥有30年的经验。最近，从2018年6月至2019年6月，她担任非营利生物技术比尔及梅林达·盖茨医学研究所的首席运营官。此前，她曾于2017年7月至2018年6月担任首席财务官，并于2016年2月至2017年7月担任ProteostasisTherapeutics，Inc.董事兼审计委员会主席2014年10月至2017年6月，她担任Forma Therapeutics，Inc.的首席财务官。2008年9月至2014年9月，Boudreau女士在Novartis担任高级财务职位，包括首席财务官Novartis Corporation US和首席财务官Global Oncology。从1999年4月到2008年9月，Boudreau女士在辉瑞公司（Pfizer）担任越来越多的战略与财务方面的职务和责任，包括Vice President金融客户业务部和商业运营部以及辉瑞全球研究与开发Vice President金融公司。Boudreau女士在百事可乐/百胜餐饮集团（PepsiCo/Yum！Brands，麦肯锡公司和美国银行。自2020年6月以来，她一直担任梦百合改进公司Premier，Inc.的董事会成员。她也任职Shattuck Labs公司、Field Trip Health公司、Rallybio公司的董事会。Boudreau女士在马里兰大学（University of Maryland）以优异成绩毕业并获得经济学学士学位，在弗吉尼亚大学（University of Virginia）达顿商学院（Darden Graduate School of Business）获得工商管理硕士学位。
- Helen M. Boudreau has served as a member of Rallybio's Board since September 2020. Since 2020, she has been Managing Director of Estuary Ventures LLC, providing board and advisory services. Previously, she served as Chief Financial Officer from July 2017 to June 2018 and as a board member from February 2016 to July 2017 of Proteostasis Therapeutics, Inc. From October 2014 to June 2017, Ms. Boudreau served as Chief Financial Officer of FORMA Therapeutics, Inc., and from September 2008 to September 2014, Ms. Boudreau served in senior finance roles at Novartis AG, including Chief Financial Officer Novartis Corporation US and Chief Financial Officer Global Oncology. Prior to Novartis, Ms. Boudreau served in roles of increasing responsibility in strategy and finance at Pfizer from April 1999 to September 2008, including Vice President Finance Customer Business Unit and Commercial Operations and Vice President Finance, Pfizer Global Research and Development. Earlier in her career, Ms. Boudreau worked at PepsiCo Inc. and YUM! Brands, Inc., McKinsey & Company and Bank of America Corporation. Ms. Boudreau currently serves as a board member of Shattuck Labs Inc. Ms. Boudreau previously served on the board of directors of Premier, Inc., Cara Therapeutics, Inc., Evaxion Biotech A/S, Proteostasis Therapeutics, Inc. and Reunion Neuroscience Inc. Ms. Boudreau earned a B.A. in Economics from the University of Maryland, where she graduated summa cum laude, and an M.B.A. from the Darden Graduate School of Business at the University of Virginia. Ms. Boudreau is Directorship Certified by the National Association of Corporate directors ("NACD") and earned the CERT Certificate in Cybersecurity Oversight from Carnegie Mellon University Software Engineering Institute and NACD.
- Lucian Iancovici
-
Lucian Iancovici自2020年5月起担任我们的董事会成员。Iancovici博士目前是TPG Growth的董事总经理，自2018年1月起在该公司工作。从2012年9月到2017年10月，Iancovici博士担任高通生命基金（Qualcomm Life Fund）的负责人，该基金是一家专注于投资数字健康技术的风险基金。从2015年1月到2017年10月，Iancovici博士是DRX Capital的普通合伙人，DRX Capital是一家由诺华和高通发起的合资投资公司。从2011年到2012年，Iancovici博士是麦肯锡公司的助理。Lucian是一名董事会认证的内科医生，在加入麦肯锡公司之前曾在纽约哥伦比亚大学医疗中心接受培训。Iancovici博士在塔夫茨大学获得了经济学学士学位和硕士学位。
Lucian Iancovici has served as a member of Rallybio's Board since May 2020. Dr. Iancovici is currently a Partner of TPG, a global alternative asset manager, where he has worked since January 2018. From September 2012 to October 2017, Dr. Iancovici served as the head of the Qualcomm Life Fund, a venture fund focused on investing in digital health technologies. From January 2015 to October 2017, Dr. Iancovici was a general partner at dRx Capital, a joint venture investment company launched by Novartis and Qualcomm. From 2011 to 2012, Dr. Iancovici was an associate at McKinsey & Company. Dr. Iancovici currently serves on the board of directors of Sionna Therapeutics, Inc. and on the boards of directors of several private companies. He is a board certified internal medicine doctor who trained at Columbia University Medical Center in New York prior to joining McKinsey & Company. Dr. Iancovici received his B.A. in economics and an M.D., both from Tufts University. - Lucian Iancovici自2020年5月起担任我们的董事会成员。Iancovici博士目前是TPG Growth的董事总经理，自2018年1月起在该公司工作。从2012年9月到2017年10月，Iancovici博士担任高通生命基金（Qualcomm Life Fund）的负责人，该基金是一家专注于投资数字健康技术的风险基金。从2015年1月到2017年10月，Iancovici博士是DRX Capital的普通合伙人，DRX Capital是一家由诺华和高通发起的合资投资公司。从2011年到2012年，Iancovici博士是麦肯锡公司的助理。Lucian是一名董事会认证的内科医生，在加入麦肯锡公司之前曾在纽约哥伦比亚大学医疗中心接受培训。Iancovici博士在塔夫茨大学获得了经济学学士学位和硕士学位。
- Lucian Iancovici has served as a member of Rallybio's Board since May 2020. Dr. Iancovici is currently a Partner of TPG, a global alternative asset manager, where he has worked since January 2018. From September 2012 to October 2017, Dr. Iancovici served as the head of the Qualcomm Life Fund, a venture fund focused on investing in digital health technologies. From January 2015 to October 2017, Dr. Iancovici was a general partner at dRx Capital, a joint venture investment company launched by Novartis and Qualcomm. From 2011 to 2012, Dr. Iancovici was an associate at McKinsey & Company. Dr. Iancovici currently serves on the board of directors of Sionna Therapeutics, Inc. and on the boards of directors of several private companies. He is a board certified internal medicine doctor who trained at Columbia University Medical Center in New York prior to joining McKinsey & Company. Dr. Iancovici received his B.A. in economics and an M.D., both from Tufts University.
- Stephen Uden
-
Stephen Uden是RallyBio的联合创始人，自2018年1月起担任总裁、首席运营官和首席科学官。此前，2014年6月至2017年10月，Uden博士担任Alexion研究高级副总裁。在Alexion之前，Uden博士在Novartis Japan、Wyeth（日本）、Neurogen和Pfizer的研究机构担任过各种领导职务。Uden博士在伦敦大学获得生物化学学士学位和医学M.B.，B.S.学位。
Stephen Uden is a co founder of, and has been Chief Executive Officer and President, and a director of, Rallybio since August 2023. From January 2018 until August 2023, Dr. Uden served as President, Chief Operating Officer and Chief Scientific Officer of Rallybio. Previously, Dr. Uden served as Senior Vice President, Research at Alexion from June 2014 to October 2017. Prior to Alexion, Dr. Uden served in various leadership roles in the research organizations of Novartis (Japan), Wyeth (Japan), Neurogen and Pfizer. Dr. Uden received a BSc in biochemistry and an M.B., B.S. in medicine from the University of London. - Stephen Uden是RallyBio的联合创始人，自2018年1月起担任总裁、首席运营官和首席科学官。此前，2014年6月至2017年10月，Uden博士担任Alexion研究高级副总裁。在Alexion之前，Uden博士在Novartis Japan、Wyeth（日本）、Neurogen和Pfizer的研究机构担任过各种领导职务。Uden博士在伦敦大学获得生物化学学士学位和医学M.B.，B.S.学位。
- Stephen Uden is a co founder of, and has been Chief Executive Officer and President, and a director of, Rallybio since August 2023. From January 2018 until August 2023, Dr. Uden served as President, Chief Operating Officer and Chief Scientific Officer of Rallybio. Previously, Dr. Uden served as Senior Vice President, Research at Alexion from June 2014 to October 2017. Prior to Alexion, Dr. Uden served in various leadership roles in the research organizations of Novartis (Japan), Wyeth (Japan), Neurogen and Pfizer. Dr. Uden received a BSc in biochemistry and an M.B., B.S. in medicine from the University of London.
- Wendy K. Chung
-
ndy K. Chung自2022年8月起担任董事会成员。Chung博士是美国医学遗传学委员会认证的临床和分子遗传学家。自2023年7月起，钟医生担任波士顿儿童医院儿科主任和哈佛医学院教师。从2014年2月到2023年7月，她在哥伦比亚大学欧文研究所领导精准医学研究。从2017年7月到2023年7月，钟博士是哥伦比亚大学肯尼迪家族儿科和医学教授，自2002年以来一直在哥伦比亚大学任教。Chung博士在康奈尔大学获得生物化学学士学位，在康奈尔大学医学院获得医学博士学位，在洛克菲勒大学获得遗传学博士学位。相信Chung博士有资格担任董事会成员，因为她在医学和研究方面的丰富经验，以及她在其他董事会的服务。
Wendy K. Chung has served as a member of Rallybio's Board since August 2022. Dr. Chung is an American Board of Medical Genetics certified clinical and molecular geneticist. Since July 2023, Dr. Chung has served as the Chair of the Department of Pediatrics at Boston Children's Hospital and on the faculty of Harvard Medical School. From February 2014 until July 2023, she led the Precision Medicine Resource in the Irving Institute at Columbia University. From July 2017 until July 2023, Dr. Chung was the Kennedy Family Professor of Pediatrics and Medicine at Columbia University, and had been on the faculty of Columbia University since 2002. Dr. Chung received her B.A. in Biochemistry from Cornell University, her M.D. from Cornell University Medical College, and her Ph.D. in Genetics from The Rockefeller University. - ndy K. Chung自2022年8月起担任董事会成员。Chung博士是美国医学遗传学委员会认证的临床和分子遗传学家。自2023年7月起，钟医生担任波士顿儿童医院儿科主任和哈佛医学院教师。从2014年2月到2023年7月，她在哥伦比亚大学欧文研究所领导精准医学研究。从2017年7月到2023年7月，钟博士是哥伦比亚大学肯尼迪家族儿科和医学教授，自2002年以来一直在哥伦比亚大学任教。Chung博士在康奈尔大学获得生物化学学士学位，在康奈尔大学医学院获得医学博士学位，在洛克菲勒大学获得遗传学博士学位。相信Chung博士有资格担任董事会成员，因为她在医学和研究方面的丰富经验，以及她在其他董事会的服务。
- Wendy K. Chung has served as a member of Rallybio's Board since August 2022. Dr. Chung is an American Board of Medical Genetics certified clinical and molecular geneticist. Since July 2023, Dr. Chung has served as the Chair of the Department of Pediatrics at Boston Children's Hospital and on the faculty of Harvard Medical School. From February 2014 until July 2023, she led the Precision Medicine Resource in the Irving Institute at Columbia University. From July 2017 until July 2023, Dr. Chung was the Kennedy Family Professor of Pediatrics and Medicine at Columbia University, and had been on the faculty of Columbia University since 2002. Dr. Chung received her B.A. in Biochemistry from Cornell University, her M.D. from Cornell University Medical College, and her Ph.D. in Genetics from The Rockefeller University.
- Martin W. Mackay
-
Martin W. Mackay是Rallybio Corporation的联合创始人、执行主席、前首席执行官和现任董事，Rallybio Corporation是一家生物技术公司，于2018年1月注册成立，最近于2021年7月成为上市公司。2013年5月至2017年6月，Mackay博士担任Alexion Pharmaceuticals， Inc.的全球研发主管；2010年7月至2013年1月，Mackay博士担任AstraZeneca PLC的研发总裁，在那里他领导研发组织，并全面负责从其管道交付新产品。Mackay博士自2018年3月起担任Novo Nordisk的董事。从2020年10月到2022年4月，Mackay博士担任5：01 Acquisition Corp.的董事，这是一家空白支票公司，其主要目的是实现业务合并，从未从事经营活动。Mackay博士自2017年7月起担任公司董事。Mackay在全球制药和生物技术公司领导研发组织的丰富经验为Charles River Laboratories International， Inc.提供了独特的专业知识组合。
Martin W. Mackay is a co founder of Rallybio and Chairman of Rallybio's Board. From January 2018 until August 2023, Dr. Mackay served as Chief Executive Officer and Chairman of the Board of Directors of Rallybio, and from August 2023 until December 2024 he served as Executive Chairman. From March 2013 to December 2017, Dr. Mackay served as the Executive Vice President and Global Head of Research & Development at Alexion Pharmaceuticals, Inc., and from July 2010 to January 2013, Dr. Mackay served as the President of Research & Development at AstraZeneca PLC. Prior to AstraZeneca, Dr. Mackay worked at Pfizer for 15 years where he held positions of increasing responsibility, including president, head of pharmatherapeutics research and development. Dr. Mackay currently serves on the board of directors of Charles River Laboratories International, Inc. and Sail Biomedicines. He previously served as a director of 5AM Acquisition Co. from October 2020 until April 2022. Dr. Mackay served on the board of Novo Nordisk from 2018 through 2025, and on the board of SpringWorks Therapeutics through its acquisition by Merck KGaA in 2025. Dr. Mackay received a BSc First Class in microbiology from Heriot Watt University and a Ph.D. in molecular genetics from the University of Edinburgh. - Martin W. Mackay是Rallybio Corporation的联合创始人、执行主席、前首席执行官和现任董事，Rallybio Corporation是一家生物技术公司，于2018年1月注册成立，最近于2021年7月成为上市公司。2013年5月至2017年6月，Mackay博士担任Alexion Pharmaceuticals， Inc.的全球研发主管；2010年7月至2013年1月，Mackay博士担任AstraZeneca PLC的研发总裁，在那里他领导研发组织，并全面负责从其管道交付新产品。Mackay博士自2018年3月起担任Novo Nordisk的董事。从2020年10月到2022年4月，Mackay博士担任5：01 Acquisition Corp.的董事，这是一家空白支票公司，其主要目的是实现业务合并，从未从事经营活动。Mackay博士自2017年7月起担任公司董事。Mackay在全球制药和生物技术公司领导研发组织的丰富经验为Charles River Laboratories International， Inc.提供了独特的专业知识组合。
- Martin W. Mackay is a co founder of Rallybio and Chairman of Rallybio's Board. From January 2018 until August 2023, Dr. Mackay served as Chief Executive Officer and Chairman of the Board of Directors of Rallybio, and from August 2023 until December 2024 he served as Executive Chairman. From March 2013 to December 2017, Dr. Mackay served as the Executive Vice President and Global Head of Research & Development at Alexion Pharmaceuticals, Inc., and from July 2010 to January 2013, Dr. Mackay served as the President of Research & Development at AstraZeneca PLC. Prior to AstraZeneca, Dr. Mackay worked at Pfizer for 15 years where he held positions of increasing responsibility, including president, head of pharmatherapeutics research and development. Dr. Mackay currently serves on the board of directors of Charles River Laboratories International, Inc. and Sail Biomedicines. He previously served as a director of 5AM Acquisition Co. from October 2020 until April 2022. Dr. Mackay served on the board of Novo Nordisk from 2018 through 2025, and on the board of SpringWorks Therapeutics through its acquisition by Merck KGaA in 2025. Dr. Mackay received a BSc First Class in microbiology from Heriot Watt University and a Ph.D. in molecular genetics from the University of Edinburgh.
- Robert Hopfner
-
Robert Hopfner， 哲学博士。2010年12月起，他担任我公司董事会成员。2002年8月起，他担任风险资本公司Bay City Capital的投资合伙人。加入 Bay City Capital之前，他担任DuPont Pharmaceuticals商业发展与战略规划部门助理和加拿大西部种子生物技术风险投资公司Ag-West Biotech的分析师。他是一家私人公司的董事会成员。他在萨省大学（University of Saskatchewan）获得药理学博士学位和药学学士学位，在芝加哥大学布斯商学院（University of Chicago Booth School of Business）获得企业、财政与战略工商管理硕士学位。
Robert Hopfner has served as a member of Rallybio's Board since March 2020. Since October 2017, Dr. Hopfner has served as a Managing Partner at Pivotal bioVenture Partners LLC, a venture capital firm. Prior to Pivotal, Dr. Hopfner served as a Principal at Bay City Capital LLC, a venture capital firm, from June 2007 to October 2009 and as a Managing Director and Partner from October 2009 to September 2017. Dr. Hopfner currently serves as a board member of Evommune, Inc., and on the boards of directors of a number of private life sciences companies. Dr. Hopfner previously served on the board of directors of Vaxcyte, Inc., Oculis Holding AG and Inozyme Pharma Inc. Dr. Hopfner received a B.Sc. in Pharmacy and a Ph.D. in Pharmacology from the University of Saskatchewan and an M.B.A. from the University of Chicago. - Robert Hopfner， 哲学博士。2010年12月起，他担任我公司董事会成员。2002年8月起，他担任风险资本公司Bay City Capital的投资合伙人。加入 Bay City Capital之前，他担任DuPont Pharmaceuticals商业发展与战略规划部门助理和加拿大西部种子生物技术风险投资公司Ag-West Biotech的分析师。他是一家私人公司的董事会成员。他在萨省大学（University of Saskatchewan）获得药理学博士学位和药学学士学位，在芝加哥大学布斯商学院（University of Chicago Booth School of Business）获得企业、财政与战略工商管理硕士学位。
- Robert Hopfner has served as a member of Rallybio's Board since March 2020. Since October 2017, Dr. Hopfner has served as a Managing Partner at Pivotal bioVenture Partners LLC, a venture capital firm. Prior to Pivotal, Dr. Hopfner served as a Principal at Bay City Capital LLC, a venture capital firm, from June 2007 to October 2009 and as a Managing Director and Partner from October 2009 to September 2017. Dr. Hopfner currently serves as a board member of Evommune, Inc., and on the boards of directors of a number of private life sciences companies. Dr. Hopfner previously served on the board of directors of Vaxcyte, Inc., Oculis Holding AG and Inozyme Pharma Inc. Dr. Hopfner received a B.Sc. in Pharmacy and a Ph.D. in Pharmacology from the University of Saskatchewan and an M.B.A. from the University of Chicago.
- Christine A. Nash
-
自2012年5月以来，Christine A. Nash担任公司高级副总裁兼首席商务官。2008年8月至2012年5月，她担任战略营销和公司业务发展副总裁，她在2007年8月加入了公司作为市场营销部高级总监。从2004年10月至2007年2月，她在CoTherix商业机构部任要职。作为CoTherix营销总监，她指挥营销和产品支持所有方面推出公司的初始产品Ventavis iloprost Inhalation Solution。她以前的经验，包括任Genesoft Pharmaceuticals Inc., Oncology Therapeutics Network, Eli Lilly 和 Company和Imana, Inc业务发展和产品规划以及管理职位。她持有斯坦福大学工商管理硕士学位及荣誉公共政策学士学位。
Christine A. Nash has served as a member of Rallybio's Board since April 2022. Since April 2018, Ms. Nash has been a principal at Chatiemac Consulting, LLC, a firm that provides strategic and commercial planning guidance to biotechnology companies and investors focused on the development of medications for rare diseases. From September 2021 until September 2022, Ms. Nash served as Board Chair and senior advisor to the President and Chief Executive Officer of The CM Group, an integrated healthcare agency focused on providing scientific and commercialization strategies and services to life sciences companies, where she also served as a member of the board of directors from August 2019 until September 2022. From 2007 to 2015, Ms. Nash held positions of increasing responsibility at Hyperion Therapeutics, Inc., including as Senior Vice President and Chief Commercial Officer since May 2012. Prior to Hyperion, from 2004 to 2007, Ms. Nash held various positions of increasing responsibility within the commercial organization at CoTherix, Inc. Ms. Nash's previous experience includes business development and product planning and management roles with Genesoft Pharmaceuticals Inc., Oncology Therapeutics Network, Eli Lilly and Company, and Imana, Inc. Ms. Nash holds an M.B.A and a B.A. with Honors in Public Policy, both from Stanford University. - 自2012年5月以来，Christine A. Nash担任公司高级副总裁兼首席商务官。2008年8月至2012年5月，她担任战略营销和公司业务发展副总裁，她在2007年8月加入了公司作为市场营销部高级总监。从2004年10月至2007年2月，她在CoTherix商业机构部任要职。作为CoTherix营销总监，她指挥营销和产品支持所有方面推出公司的初始产品Ventavis iloprost Inhalation Solution。她以前的经验，包括任Genesoft Pharmaceuticals Inc., Oncology Therapeutics Network, Eli Lilly 和 Company和Imana, Inc业务发展和产品规划以及管理职位。她持有斯坦福大学工商管理硕士学位及荣誉公共政策学士学位。
- Christine A. Nash has served as a member of Rallybio's Board since April 2022. Since April 2018, Ms. Nash has been a principal at Chatiemac Consulting, LLC, a firm that provides strategic and commercial planning guidance to biotechnology companies and investors focused on the development of medications for rare diseases. From September 2021 until September 2022, Ms. Nash served as Board Chair and senior advisor to the President and Chief Executive Officer of The CM Group, an integrated healthcare agency focused on providing scientific and commercialization strategies and services to life sciences companies, where she also served as a member of the board of directors from August 2019 until September 2022. From 2007 to 2015, Ms. Nash held positions of increasing responsibility at Hyperion Therapeutics, Inc., including as Senior Vice President and Chief Commercial Officer since May 2012. Prior to Hyperion, from 2004 to 2007, Ms. Nash held various positions of increasing responsibility within the commercial organization at CoTherix, Inc. Ms. Nash's previous experience includes business development and product planning and management roles with Genesoft Pharmaceuticals Inc., Oncology Therapeutics Network, Eli Lilly and Company, and Imana, Inc. Ms. Nash holds an M.B.A and a B.A. with Honors in Public Policy, both from Stanford University.
- Ronald Hunt
-
Ronald Hunt，他担任董事（2012年7月以来）。他曾一直担任New Leaf Venture Partners公司（风险资本公司）的董事总经理（2005年以来），专注于投资生物制药公司。此前，他曾任职the Sprout Group（风险资本公司），担任cCoopers & Lybrand Consulting公司和The Health Care Group的咨询公司的顾问。进入咨询领域之前，他曾担任Johnson & Johnson公司和SmithKline Beecham Pharmaceuticals公司的多种销售和市场营销职位。他目前任职于Durata Therapeutics公司（一个制药公司）的董事会。他持有Cornell大学的工商管理和市场营销学士学位，以及Pennsylvania大学沃顿商学院的工商管理硕士学位。
Ronald Hunt has served as a member of Rallybio's Board since 2018. Since 2005, Mr. Hunt has served as a Managing Director and Member of New Leaf Venture Partners, L.L.C., a venture capital firm. Previously, Mr. Hunt served at the Sprout Group, a venture capital firm and was a consultant with consulting firms Coopers & Lybrand Consulting and The Health Care Group, Inc. Mr. Hunt worked earlier in his career in various sales and marketing positions at Johnson & Johnson and SmithKline Beecham Pharmaceuticals PLC. Mr. Hunt currently serves as a director of Iterum Therapeutics, Ltd., a clinical stage company, and on the boards of a number of private pharmaceutical and healthcare companies. Mr. Hunt previously served on the board of directors of Harpoon Therapeutics, Inc. Mr. Hunt received a B.S. from Cornell University and an M.B.A. from the Wharton School of the University of Pennsylvania. - Ronald Hunt，他担任董事（2012年7月以来）。他曾一直担任New Leaf Venture Partners公司（风险资本公司）的董事总经理（2005年以来），专注于投资生物制药公司。此前，他曾任职the Sprout Group（风险资本公司），担任cCoopers & Lybrand Consulting公司和The Health Care Group的咨询公司的顾问。进入咨询领域之前，他曾担任Johnson & Johnson公司和SmithKline Beecham Pharmaceuticals公司的多种销售和市场营销职位。他目前任职于Durata Therapeutics公司（一个制药公司）的董事会。他持有Cornell大学的工商管理和市场营销学士学位，以及Pennsylvania大学沃顿商学院的工商管理硕士学位。
- Ronald Hunt has served as a member of Rallybio's Board since 2018. Since 2005, Mr. Hunt has served as a Managing Director and Member of New Leaf Venture Partners, L.L.C., a venture capital firm. Previously, Mr. Hunt served at the Sprout Group, a venture capital firm and was a consultant with consulting firms Coopers & Lybrand Consulting and The Health Care Group, Inc. Mr. Hunt worked earlier in his career in various sales and marketing positions at Johnson & Johnson and SmithKline Beecham Pharmaceuticals PLC. Mr. Hunt currently serves as a director of Iterum Therapeutics, Ltd., a clinical stage company, and on the boards of a number of private pharmaceutical and healthcare companies. Mr. Hunt previously served on the board of directors of Harpoon Therapeutics, Inc. Mr. Hunt received a B.S. from Cornell University and an M.B.A. from the Wharton School of the University of Pennsylvania.
- Paula Soteropoulos
-
Paula Soteropoulos，自2013年7月开始，一直担任监事会的成员。从2013年7月起，Soteropoulos女士还一直担任Moderna Therapeutics, Inc.心脏疗法的商业和战略联盟部门的高级副总裁兼总经理。在这以前，从1992到2013年，Soteropoulos女士曾在Genzyme公司就职，一家生物技术公司，最近担任的职位是罕见心血管疾病部门的副总裁和总经理。Soteropoulos女士持有Tufts大学化学工程学位学士学位和生物化学工程硕士学位，以及Virginia大学达顿商学院的工商管理研究生院的行政管理证书。
Paula Soteropoulos has served as a member of Rallybio's Board since October 2020. Ms. Soteropoulos currently serves as Chairman of Ensoma, a private venture backed company, serves on the board of directors of Metri Bio and Dianthus Therapeutics, Inc. She previously served as Chief Executive Officer and President of Akcea Therapeutics, Inc. a biopharmaceutical company, where she was also a member of the board of directors. Prior to Akcea, Ms. Soteropoulos served as Senior Vice President and General Manager, Cardiometabolic Business and Strategic Alliances at Moderna Therapeutics Inc., and prior to Moderna, she served in various roles of increasing responsibility at Genzyme Corporation, including as Vice President and General Manager, Cardiovascular, Rare Diseases. Ms. Soteropoulos served for 11 years on the board of directors of uniQure N.V. Ms. Soteropoulos also serves on advisory boards of Chiesi USA and Kyowa Kirin North America. Ms. Soteropoulos earned both a B.S. in chemical and biochemical engineering and an M.S. in chemical and biochemical engineering from Tufts University, and holds an executive management certificate from the Darden Graduate School of Business at the University of Virginia. Ms. Soteropoulos serves on the Advisory Board for the Chemical and Biological Engineering Department of Tufts University. - Paula Soteropoulos，自2013年7月开始，一直担任监事会的成员。从2013年7月起，Soteropoulos女士还一直担任Moderna Therapeutics, Inc.心脏疗法的商业和战略联盟部门的高级副总裁兼总经理。在这以前，从1992到2013年，Soteropoulos女士曾在Genzyme公司就职，一家生物技术公司，最近担任的职位是罕见心血管疾病部门的副总裁和总经理。Soteropoulos女士持有Tufts大学化学工程学位学士学位和生物化学工程硕士学位，以及Virginia大学达顿商学院的工商管理研究生院的行政管理证书。
- Paula Soteropoulos has served as a member of Rallybio's Board since October 2020. Ms. Soteropoulos currently serves as Chairman of Ensoma, a private venture backed company, serves on the board of directors of Metri Bio and Dianthus Therapeutics, Inc. She previously served as Chief Executive Officer and President of Akcea Therapeutics, Inc. a biopharmaceutical company, where she was also a member of the board of directors. Prior to Akcea, Ms. Soteropoulos served as Senior Vice President and General Manager, Cardiometabolic Business and Strategic Alliances at Moderna Therapeutics Inc., and prior to Moderna, she served in various roles of increasing responsibility at Genzyme Corporation, including as Vice President and General Manager, Cardiovascular, Rare Diseases. Ms. Soteropoulos served for 11 years on the board of directors of uniQure N.V. Ms. Soteropoulos also serves on advisory boards of Chiesi USA and Kyowa Kirin North America. Ms. Soteropoulos earned both a B.S. in chemical and biochemical engineering and an M.S. in chemical and biochemical engineering from Tufts University, and holds an executive management certificate from the Darden Graduate School of Business at the University of Virginia. Ms. Soteropoulos serves on the Advisory Board for the Chemical and Biological Engineering Department of Tufts University.
高管简历
中英对照 | 中文 | 英文- Stephen Uden
Stephen Uden是RallyBio的联合创始人，自2018年1月起担任总裁、首席运营官和首席科学官。此前，2014年6月至2017年10月，Uden博士担任Alexion研究高级副总裁。在Alexion之前，Uden博士在Novartis Japan、Wyeth（日本）、Neurogen和Pfizer的研究机构担任过各种领导职务。Uden博士在伦敦大学获得生物化学学士学位和医学M.B.，B.S.学位。
Stephen Uden is a co founder of, and has been Chief Executive Officer and President, and a director of, Rallybio since August 2023. From January 2018 until August 2023, Dr. Uden served as President, Chief Operating Officer and Chief Scientific Officer of Rallybio. Previously, Dr. Uden served as Senior Vice President, Research at Alexion from June 2014 to October 2017. Prior to Alexion, Dr. Uden served in various leadership roles in the research organizations of Novartis (Japan), Wyeth (Japan), Neurogen and Pfizer. Dr. Uden received a BSc in biochemistry and an M.B., B.S. in medicine from the University of London.- Stephen Uden是RallyBio的联合创始人，自2018年1月起担任总裁、首席运营官和首席科学官。此前，2014年6月至2017年10月，Uden博士担任Alexion研究高级副总裁。在Alexion之前，Uden博士在Novartis Japan、Wyeth（日本）、Neurogen和Pfizer的研究机构担任过各种领导职务。Uden博士在伦敦大学获得生物化学学士学位和医学M.B.，B.S.学位。
- Stephen Uden is a co founder of, and has been Chief Executive Officer and President, and a director of, Rallybio since August 2023. From January 2018 until August 2023, Dr. Uden served as President, Chief Operating Officer and Chief Scientific Officer of Rallybio. Previously, Dr. Uden served as Senior Vice President, Research at Alexion from June 2014 to October 2017. Prior to Alexion, Dr. Uden served in various leadership roles in the research organizations of Novartis (Japan), Wyeth (Japan), Neurogen and Pfizer. Dr. Uden received a BSc in biochemistry and an M.B., B.S. in medicine from the University of London.
- Jonathan I. Lieber
Jonathan I. Lieber自2021年9月起担任Applied Genetic Technologies Corporation首席财务官。从2018年12月到2021年9月，Lieber先生担任生物技术融资和会计咨询公司Danforth Advisors的董事总经理。Lieber先生曾于2015年6月至2018年12月担任Histogenics Corporation的首席财务官，该公司是一家专注于开发恢复性细胞疗法的生物制药公司。在此之前，他于2014年1月至2015年6月担任Metamark Genetics，Inc.的高级副总裁兼首席财务官，Metamark Genetics，Inc.是一家专注于泌尿科的私营分子诊断公司。2012年9月至2013年9月，Lieber先生担任生命科学行业高价值耗材制造商和供应商Repligen Corporation的首席财务官和财务主管。2009年6月至2012年5月，Lieber先生担任Xcellerex，Inc.的首席财务官和财务主管，该公司是一家私营公司，从事为生物制药行业制造和销售资本设备和相关消耗品。自2020年6月以来，Lieber先生一直在专注于癌症的生物技术公司Salarius制药的董事会任职。Lieber先生获得了纽约大学斯特恩商学院的金融学工商管理硕士学位和理学学士学位。
Jonathan I. Lieber has been Chief Financial Officer and Treasurer of Rallybio since February 2023. Previously, Mr. Lieber, served as the Chief Financial Officer of Applied Genetic Technologies Corporation, a publicly traded clinical stage biotechnology company, from September 2021 until November 2022. From December 2018 until September 2021, Mr. Lieber was a Managing Director at Danforth Advisors, a firm providing strategic and operational finance and accounting for life science companies. From July 2015 until December 2018, Mr. Lieber served as Chief Financial Officer of Histogenics Corporation, a publicly traded cell therapy company. Mr. Lieber also served as the Chief Financial Officer of Metamark Genetics, Inc., Repligen Corporation, Xcellerex, Inc., and Altus Pharmaceuticals. Mr. Lieber began his career in healthcare as an investment banker at Salomon Brothers/Salomon Smith Barney and SG Cowen. He has been a member of the board of directors of Decoy Therapeutics, Inc. (Nasdaq: DCOY) since June 2020, Mindwalk Holdings Corp. (Nasdaq: HYFT) since July 2025 and Zola Pharmaceuticals (private) since February 2024. Mr. Lieber received a B.S. in business administration and finance from Boston University and an M.B.A. in finance from New York University's Leonard N. Stern School of Business.- Jonathan I. Lieber自2021年9月起担任Applied Genetic Technologies Corporation首席财务官。从2018年12月到2021年9月，Lieber先生担任生物技术融资和会计咨询公司Danforth Advisors的董事总经理。Lieber先生曾于2015年6月至2018年12月担任Histogenics Corporation的首席财务官，该公司是一家专注于开发恢复性细胞疗法的生物制药公司。在此之前，他于2014年1月至2015年6月担任Metamark Genetics，Inc.的高级副总裁兼首席财务官，Metamark Genetics，Inc.是一家专注于泌尿科的私营分子诊断公司。2012年9月至2013年9月，Lieber先生担任生命科学行业高价值耗材制造商和供应商Repligen Corporation的首席财务官和财务主管。2009年6月至2012年5月，Lieber先生担任Xcellerex，Inc.的首席财务官和财务主管，该公司是一家私营公司，从事为生物制药行业制造和销售资本设备和相关消耗品。自2020年6月以来，Lieber先生一直在专注于癌症的生物技术公司Salarius制药的董事会任职。Lieber先生获得了纽约大学斯特恩商学院的金融学工商管理硕士学位和理学学士学位。
- Jonathan I. Lieber has been Chief Financial Officer and Treasurer of Rallybio since February 2023. Previously, Mr. Lieber, served as the Chief Financial Officer of Applied Genetic Technologies Corporation, a publicly traded clinical stage biotechnology company, from September 2021 until November 2022. From December 2018 until September 2021, Mr. Lieber was a Managing Director at Danforth Advisors, a firm providing strategic and operational finance and accounting for life science companies. From July 2015 until December 2018, Mr. Lieber served as Chief Financial Officer of Histogenics Corporation, a publicly traded cell therapy company. Mr. Lieber also served as the Chief Financial Officer of Metamark Genetics, Inc., Repligen Corporation, Xcellerex, Inc., and Altus Pharmaceuticals. Mr. Lieber began his career in healthcare as an investment banker at Salomon Brothers/Salomon Smith Barney and SG Cowen. He has been a member of the board of directors of Decoy Therapeutics, Inc. (Nasdaq: DCOY) since June 2020, Mindwalk Holdings Corp. (Nasdaq: HYFT) since July 2025 and Zola Pharmaceuticals (private) since February 2024. Mr. Lieber received a B.S. in business administration and finance from Boston University and an M.B.A. in finance from New York University's Leonard N. Stern School of Business.